Redefining the Adjuvant Landscape and Radiation Sequencing in Merkel Cell Carcinoma

For healthcare providers managing cutaneous malignancies, Merkel Cell Carcinoma (MCC) has long represented one of the most formidable clinical challenges. This rare, neuroendocrine skin cancer is notorious for its aggressive biology, propensity for rapid locoregional tracking, and high rate of distant failure. Historically, the therapeutic toolkit for advanced or high-risk localized disease was severely constrained, relying on wide surgical margins, regional radiotherapy, and highly toxic, non-durable cytotoxic chemotherapy regimens.

2026 ASCO Annual Meeting

During the 2026 ASCO Annual Meeting, a session on new oncology medications and their incorporation into clinical practice highlighted several recently FDA-approved agents. Speakers put these agents into context for clinicians, discussing safe dosage, potential adverse events, disease management, and other important factors for the administration of these new approvals and updates.

The therapeutic architecture of MCC is undergoing a dramatic evolution. The integration of immune checkpoint inhibitors (ICIs) has already revolutionized the treatment of metastatic disease. Now, landmark data from clinical trials are shifting the focus to the adjuvant setting, offering new options to intercept disease recurrence early. Most notably, the updated outcomes from the Phase III ECOG-ACRIN EA6174 (STAMP) trial presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting have introduced definitive evidence that will reshape how we sequence multimodality therapy for resected, high-risk MCC.

Why It Matters

The High Stakes of Post-Surgical Recurrence

To appreciate the significance of recent adjuvant breakthroughs, we must confront the sobering clinical reality of MCC. While the annual incidence of MCC is relatively low—standing at approximately 0.7 cases per 100,000 individuals in the United States —its mortality rate eclipses that of malignant melanoma.

The Survival and Recurrence Dilemma

Historically, the 5-year overall survival (OS) rate for localized MCC hovered around 50%. Once the disease spread to regional lymph nodes (Stage III), that figure dropped to approximately 35% and plummeted to a dismal 14% in the face of distant metastasis. While first-line anti-PD-(L)1 agents like avelumab and pembrolizumab have significantly pushed the needle in metastatic disease—extending median overall survival to 20.3 months and 24.3 months, respectively —preventing the transition from localized to metastatic disease remains the holy grail of treatment.

Surgical clear margins alone do not equal a cure in MCC. A comprehensive meta-analysis of 926 cases revealed that even after achieving pathologically clear margins, patients faced extraordinary recurrence risks:

• Local Recurrence Rate (LRR): 16.4%
• Regional Nodal Recurrence Rate (RRR): 32.1%
• In-Transit Recurrence Rate (ITR): 9.5%
• Distant Recurrence Rate (DRR): 9.5%

Furthermore, these recurrences manifest with alarming speed. The median time to relapse is a narrow 7 to 9 months post-treatment, with the vast majority of recurrences taking place within the first 24 months. This tight clinical window demands highly effective, front-loaded adjuvant strategies capable of eradicating hidden microscopic disease before it establishes macro-metastatic niches.

The STAMP Trial: Dissecting True Efficacy

The Phase III STAMP trial is a critical milestone because it is the first randomized Phase III trial evaluating adjuvant pembrolizumab in resected Stage I (without sentinel lymph node biopsy) through Stage IIIB MCC. The trial randomized 293 patients 1:1 to receive either pembrolizumab (200 mg IV every 3 weeks for up to 17 doses) or standard of care (SOC) observation.

The trial reported a critical nuance in its endpoints that every clinician must understand:

• *Overall Relapse-Free Survival (RFSa): Defined as relapse due to recurrence or death from any cause, RFSa was numerically superior in the pembrolizumab arm but did not achieve statistical significance (p = 0.10*).
• *MCC-Specific Relapse-Free Survival (RFSb): Defined strictly as MCC-specific recurrence and death, pembrolizumab demonstrated a powerful, statistically significant benefit (p = 0.032) with a Hazard Ratio (HR) of 0.66. This translated to a 1-year RFSb* rate of 84% and a 2-year rate of 77% for the pembrolizumab arm, compared to 73% and 67% for observation.
• Distant Metastasis-Free Survival (DMFS): Pembrolizumab significantly extended DMFS (p = 0.05), validating its role in shutting down distant hematogenous seeding.

*Why the discordance between RFSa and RFSb? The trial investigators noted that the median age of the cohort was 69 years, and more than half of the patients were accrued during the height of the COVID-19 pandemic. In this elderly, vulnerable population, non-cancer-related mortalities and pandemic-associated disruptions diluted the all-cause RFSa endpoint. Therefore, RFSb* (MCC-specific survival) emerges as the truer, cleaner indicator of pembrolizumab’s biological and clinical efficacy.

Who It Affects

Identifying the High-Risk Patient Profiles

As we move toward an era of precision oncology, a “one-size-fits-all” approach to MCC is no longer defensible. Understanding which patients stand to benefit most from adjuvant checkpoint inhibition requires a dual understanding of clinical staging and the divergent molecular pathways driving this disease.

The Molecular Dichotomy: Viral Status and Mutation Burden

MCC is driven by two entirely separate oncogenic mechanisms, each resulting in distinct immune microenvironments and clinical trajectories:

1. Virus-Positive MCC (VP-MCC): Accounts for approximately 80% of cases in the United States. It is driven by the clonal integration of the Merkel Cell Polyomavirus (MCPyV) into the host genome. The expression of viral oncoproteins (specifically the Large T antigen) inactivates key tumor suppressors like p53 and RB1. VP-MCC is characterized by a low tumor mutational burden (TMB) but a highly immunogenic profile, featuring prominent CD8+ T-cell infiltration and elevated PD-L1 expression. This makes VP-MCC highly sensitive to immunotherapy, resulting in a far superior median overall survival of 6.6 years.
2. Virus-Negative MCC (VN-MCC): Predominantly dominant in regions with extreme UV indices, such as Australia. This subtype is driven purely by chronic, severe ultraviolet (UV) radiation, which creates characteristic cyclobutene pyrimidine dimers (CPDs) and 6-4 photoproducts, causing widespread genomic instability. VN-MCC exhibits a remarkably high tumor mutational burden (TMB) populated by frequent, direct inactivating mutations of TP53 and RB1. Clinically, it features lower CD8+ T-cell densities, a less predictable response to ICIs, and a vastly inferior median overall survival of just 1.2 years.

Vulnerable and Immunosuppressed Cohorts

MCC preferentially strikes fair-skinned, older adults (median age of onset around 70 years), matching decades of cumulative UV damage and age-related immunosenescence. However, clinicians must maintain a high index of suspicion and an aggressive treatment stance in severely immunocompromised populations.

Solid organ transplant recipients, individuals living with HIV, and patients with hematologic malignancies (such as follicular lymphoma or chronic lymphocytic leukemia) experience up to a 13-fold increased risk of developing MCC. Furthermore, patients with chronic inflammatory states (e.g., rheumatoid arthritis, diabetes, and hepatitis B) exhibit impaired immune surveillance that accelerates tumor progression.

Alarmingly, these immunosuppressed cohorts face a double-edged sword: they are more likely to present with aggressive, high-stage disease, yet they exhibit markedly diminished response rates to traditional immunotherapy due to their compromised baseline T-cell functions. This makes the identification of optimized combination regimens and precise therapeutic sequencing a clinical priority for these individuals.

What Changes

Redefining Clinical Workflows and Radiation Sequencing

The STAMP trial does more than just add pembrolizumab as a viable adjuvant option alongside the data established by the prior ADMEC-O trial (which validated adjuvant nivolumab). Its most profound, practice-changing revelation lies in how we combine immunotherapy with radiation therapy.

The Sequencing Secret: Sequential, Not Concurrent

Radiotherapy has long been an essential tool in localized MCC to optimize regional control, particularly in cases with high-risk features like lymphovascular invasion, perineural tracking, large primary tumors (>1 cm), or positive sentinel lymph nodes. Historically, radiation was thought to synergize with ICIs primarily by altering the tumor microenvironment, destroying tumor cells to release neoantigens, and priming T-cell infiltration.

However, the STAMP trial revealed a striking divergence based on the timing of these modalities:

• Concurrent Administration: For patients who received pembrolizumab concurrently with radiation therapy, the addition of the ICI failed to show any statistical benefit over standard care.
• Sequential Administration: Conversely, for patients who completed their radiation therapy prior to randomization/initiation of pembrolizumab (n = 68 pembro, n = 65 SOC), adjuvant pembrolizumab delivered extraordinary clinical benefits. In this sequential subset, pembrolizumab drastically improved all major clinical metrics, including RFSa (p = 0.014), RFSb (p = 0.009), and DMFS (p = 0.004).

This finding aligns with emerging data across other solid tumors, suggesting that concurrent delivery may result in radiation-induced lymphopenia or localized immune exhaustion, effectively killing off the very activated T-cell populations that checkpoint inhibitors rely on to function. By allowing radiation to first clear the heavy local microscopic disease burden and establish an inflamed microenvironment, subsequent sequential delivery of pembrolizumab maximizes systemic immune-mediated clearance.

The Evolving Multidisciplinary Workup and Algorithm

To integrate these insights, multidisciplinary tumor boards must adapt their local management algorithms:

1. Suspicion and Visual Awareness: Given that MCC routinely mimics benign lesions like cherry angiomas or common basal cell carcinomas, any rapidly growing, painless, red-to-violaceous nodule on sun-exposed areas (especially the head and neck, which comprises > 50% of cases) must be biopsied immediately.
2. Pathological and IHC Confirmation: Histopathological analysis remains the gold standard. Diagnosis must be confirmed via a comprehensive immunohistochemical panel showing classic perinuclear, dot-like cytokeratin 20 (CK20) expression, paired with neuroendocrine markers such as synaptophysin and chromogranin.
3. Staging and Regional Assessment: Following confirmation, patients should undergo systemic staging via FDG-PET/CT. Crucially, even for small primary lesions (< 1 cm), a Sentinel Lymph Node Biopsy (SLNB) must be performed at the time of wide local excision (WLE) or Mohs micrographic surgery. Roughly 24% to 32% of clinically node-negative patients harbor occult nodal disease that can only be uncovered via SLNB.
4. Adjuvant Architecture: If high-risk features or nodal involvement (Stage III) are confirmed, patients should proceed directly to regional radiotherapy. In accordance with the STAMP data, adjuvant immunotherapy with pembrolizumab should be initiated sequentially immediately after the completion of the radiation course, rather than overlapping with it.

Post-Treatment Surveillance: Enter the Liquid Biopsy

What changes during the follow-up phase? Clinical surveillance is shifting away from purely anatomical imaging toward highly sensitive molecular assays.

Because MCC carries a lifelong risk of recurrence and a significantly elevated risk for secondary primary malignancies (including a 3.09 standardized incidence ratio for malignant melanoma), surveillance must be rigorous. Advanced tracking now utilizes circulating tumor DNA (ctDNA) monitoring alongside longitudinal monitoring of MCPyV oncoprotein antibody titers. In virus-positive patients, a serological spike in viral antibody titers serves as an ultra-early, non-invasive herald of hidden micro-recurrence, allowing clinicians to initiate proactive multi-modal imaging and salvage therapies months before a lesion becomes visible or symptomatic.

The Bottom Line for Clinical Practices

The treatment of Merkel Cell Carcinoma has moved decisively past the era of standard toxic chemotherapy, which is now rightfully reserved for rapid cytoreduction or palliative symptom control.

The updated results of the STAMP trial give healthcare providers a clear directive: for patients with resected, high-risk Merkel Cell Carcinoma, adjuvant immunotherapy significantly mitigates disease-specific recurrence and prevents distant metastatic failure. To achieve maximum therapeutic efficacy, we must respect the biological interplay between radiation and the immune response: deliver radiotherapy completely and follow it sequentially with adjuvant pembrolizumab. By implementing this structured, multidisciplinary sequence, we can finally begin to close the loop on recurrences and alter the survival trajectory of this aggressive disease.

References

1. https://clinicaltrials.gov/study/NCT03712605
2. Mehnert, Janice. Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174. Paper presented at: 2026 ASCO (American Society of Clinical Oncology) Annual Meeting; June 1, 2026; Chicago, Illinois.